Invest now
Alivus Life Sciences share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹1,383.05(-0.63%)September 11, 2026 15:28:58 PM IST
- NSE
- BSE
- Vol : 80.56 K (NSE + BSE)Last 20 day avg : 193.60 K
Alivus Life Sciences is trading -0.63% lower at Rs 1,383.05 as compared to its last closing price. Alivus Life Sciences has been trading in the price range of 1,395.00 & 1,375.85. Alivus Life Sciences has given 51.67% in this year & -2.02% in the last 5 days. Alivus Life Sciences has TTM P/E ratio 23.55 as compared to the sector P/E of 36.32.There are 4 analysts who have initiated coverage on Alivus Life Sciences. There are 2 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 160.08 Crores in its last quarter.Listed peers of Alivus Life Sciences include Sun Pharmaceutical Industries (-1.18%), Divi's Laboratories (-0.84%), Torrent Pharmaceuticals (0.95%).The Mutual Fund holding in Alivus Life Sciences was at 5.65% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Alivus Life Sciences was at 5.54% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 14 Sep 2026, 09:02 AM IST
- BetaLow volatility0.77Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.02The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.36Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation4.43The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Alivus Life Sciences News
Alivus Life Sciences Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,842.00 | -1.18 | 4,41,947.09 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,326.00 | -0.84 | 2,47,576.00 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,975.00 | 0.95 | 1,89,226.24 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,365.00 | -1.09 | 1,10,119.20 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,119.50 | 0.13 | 1,11,670.56 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allAlivus Life Sciences Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-30 | Quarterly Results |
| 2026-05-14 | Audited Results & Final Dividend |
| 2026-01-22 | Quarterly Results |
| 2025-11-06 | Quarterly Results |
| 2025-08-01 | Quarterly Results |
About the company Alivus Life Sciences
- IndustryBiotechnology & Drugs
- ISININE03Q201024
- BSE Code543322
- NSE CodeALIVUS
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh.
Alivus Life Sciences Share Price FAQs
Alivus Life Sciences is trading at 1383.05 as on Fri Sep 11 2026 09:58:58. This is -0.63% lower as compared to its previous closing price of 1391.85.
The market capitalization of Alivus Life Sciences is 17005.69 Cr as on Fri Sep 11 2026 09:58:58.
The average broker rating on Alivus Life Sciences is Strong Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 2 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Alivus Life Sciences is 1495.30 whereas the 52 wk low is 830.00
Alivus Life Sciences can be analyzed on the following key metrics -
- TTM P/E: 23.55
- Sector P/E: 36.32
- Dividend Yield: 0.36%
- D/E ratio: -
Alivus Life Sciences reported a net profit of 564.48 Cr in 2026.
The Mutual Fund Shareholding was 5.65% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Alivus Life Sciences QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.